Baxter AG and Jerini AG today announced progress in their collaborative research program to develop a non-intravenous therapy for the treatment of hemophilia. Extensive in vitro and in vivo analysis has identified several synthetic lead molecules with promising pharmacological properties.
Medical News Today (http://www.medicalnewstoday.com/medicalnews.php?newsid=45544)
